Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03012880 | Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03448393 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies |
| completed |
| Phase 1 |
| 54 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jun 4, 2025 |
| clinicaltrials |
| NCT06422247 | Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy | completed | — | 307 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT05142371 | Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors | completed | N/A | 33 | City of Hope Medical CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03870945 | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) | completed | Phase 1 | 12 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT04696432 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 7 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT03490344 | Short Course Daratumumab in Patients With Multiple Myeloma | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04042376 | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | completed | Phase 4 | 17 | Janssen Research & Development, LLCINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT04062448 | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT02519452 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT03113422 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy(PrE0403) | completed | Phase 2 | 56 | PrECOG, LLC.OTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma(KarMMa) | completed | Phase 2 | 149 | CelgeneINDUSTRY | 8 | May 23, 2025 | clinicaltrials |
| NCT03941860 | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | completed | Phase 3 | 1 | National Cancer Institute (NCI)NIH | 2 | May 23, 2025 | clinicaltrials |
| NCT04317885 | A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | completed | Phase 1 | 25 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04655677 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT05958134 | Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL | completed | — | 600 | AstraZenecaINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT04176380 | RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma | completed | Phase 2 | 15 | Rapa Therapeutics LLCINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT04240808 | Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT00368784 | T Cell Repertoire Analysis of Immune Mediated Skin Diseases | completed | — | 426 | University of California, DavisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | CelgeneINDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT00179673 | Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 43 | CelgeneINDUSTRY | 2 | May 13, 2025 | clinicaltrials |
| NCT03295240 | The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04402138 | Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | completed | Phase 2 | 15 | SCRI Development Innovations, LLCOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT01729091 | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT04034056 | Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)(URBAN) | completed | — | 299 | Hoffmann-La RocheINDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT01184885 | A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | completed | Early Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05053100 | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | completed | — | 100 | Mayo ClinicOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02076009 | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 569 | Janssen Research & Development, LLCINDUSTRY | 18 | May 1, 2025 | clinicaltrials |
| NCT03417284 | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT00135200 | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01458366 | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | completed | Phase 1 / Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02224729 | Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03277105 | A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 522 | Janssen Research & Development, LLCINDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT03412565 | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | completed | Phase 2 | 265 | Janssen Research & Development, LLCINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT04100044 | Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma | completed | N/A | 9 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT01998971 | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | completed | Phase 1 | 240 | Janssen Research & Development, LLCINDUSTRY | 3 | Apr 25, 2025 | clinicaltrials |
| NCT03939182 | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05347485 | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | completed | Phase 2 | 86 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05673967 | Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma | completed | — | 62 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02566304 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03860038 | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 113 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 24, 2025 | clinicaltrials |
| NCT04578600 | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | completed | Phase 1 | 8 | Joseph TuscanoOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05690230 | Improving Patient Experience: BMBA | completed | N/A | 60 | Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04566978 | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) | completed | Early Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 5, 2025source: clinicaltrials